IL6 and COVID-19: Though there is more evidence currently toward reducing the severity of COVID-19-related AKI in transplant recipients with the use of steroids and interleukin 6 (IL-6) receptor antagonists, treatment for patients included in our study was guided by institutional protocols based on the evidence available at the onset of the COVID-19 pandemic and kept evolving with time [16].